Clinical Trial

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

Study acronym: EXCALIBUR-ET2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-07
notable Trial sites expanded: 0 -> 180 locations 2026-08-07
Trial Details
NCT Number NCT07623200
Lead Sponsor Incyte Corporation
Conditions Essential Thrombocythemia
Enrollment 426 participants
Start Date 2026-09-08
Primary Completion 2029-06-15 (estimated)
Study Completion 2030-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06